Use of Phenotypically Poor Metabolizer Individual Donor
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Dexmedetomidine)
Frequently asked questions regarding alpha-2 agonist DEXDOMITOR® (dexmedetomidine) Q: How should I monitor a patient that has received DEXDOMITOR for sedation or as a premedication? A: The monitoring of vital signs is critical for any patient under sedation or anesthesia. It is important to monitor heart rate, blood pressure, palpable pulse quality, and respiratory rate and volume. Because a2 agonists cause peripheral vasoconstriction, the use of pulse oximetry may not adequately reflect the true status of the patient. Q: What can I expect to see in a patient under DEXDOMITOR sedation? A: The patient may have pale pink or grayish mucous membranes because of peripheral vasoconstriction. The sedation induced by DEXDOMITOR causes a decrease in respiratory rate and a lower body temperature. Q: What is considered a low heart rate? A: Because of the wide range of dog sizes and corresponding heart rates, normal heart rates should be based on the dog’s body size. A reduction in heart rate following a2 agonist sedation should be expected. Patient status should be evaluated by the simultaneous measurement of many parameters, including pulse quality, respiratory rate and quality, blood pressure, and heart rate. Q: What is the effect on the respiratory rate? A: DEXDOMITOR does not have a direct effect on respiration. Although the respiratory rate may decrease as a result of sedation, ventilatory volume generally increases, and overall ventilation (gas exchange) remains stable. Q: I am concerned about hypothermia. A: Hypothermia can occur in a patient following administration of any anesthetic or sedative drug. It is important that body temperature be maintained in all patients undergoing anesthesia or sedation, including those that receive an a2 agonist. -
(12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig. -
Customs Tariff - Schedule
CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2020 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels. -
)&F1y3x PHARMACEUTICAL APPENDIX to THE
)&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE -
Download a Drug Interactions Card
transplant.bc.ca/medications Please discuss with your healthcare professionals BEFORE starting or stopping any medications, herbal or non-prescription products. Contact your Transplant Clinic nurse or pharmacist to let them know if there are any changes to your medications. Transplant Clinic Phone: _____________________________________ BC PHN (CareCard #) __________________________________ (2017v3) Please call your transplant clinic before starting any new medications to avoid possible drug interactions, especially those with CAUTION (see below) next to its name: Cyclosporine (Neoral), Tacrolimus (Prograf/Sandoz tac, Advagraf), Sirolimus (Rapamune): Seizure: phenytoin, carbamazepine, phenobarbital, primidone Infection: erythromycin, clarithromycin – CAUTION ( OK- azithromycin) fluconazole, ketoconzazole, posaconazole voriconazole - CAUTION rifampin – CAUTION Cyclosporine (Neoral), Tacrolimus (Prograf/Sandoz tac, d Advagraf), Sirolimus (Rapamune) cont’d Depression: fluoxetine, fluvoxamine ( OK- paroxetine, citalopram, escitalopram, sertraline, venlafaxine, mirtazapine) Heart/Blood pressure: diltiazem, verapamil, amiodarone, digoxin Cholesterol: lovastatin, simvastatin, atorvastatin ( OK- rosuvastatin, pravastatin, fluvastatin) Pain: anti-inflammatories can affect kidney function: ibuprofen, naproxen, diclofenac, indomethacin, celecoxib ( OK- acetaminophen) Mycophenolate mofetil/sodium (MMF, Cellcept/Myfortic): Antacids: space taking antacid and MMF by 2 hours Cholestyramine: AVOID if possible Azathioprine (Imuran): Gout: allopurinol – -
PACKAGE LEAFLET: INFORMATION for the PATIENT Desloratadine 5
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT Desloratadine 5 mg tablets Read all of this leaflet carefully before you start taking/using this medicine because it contains important information for you. Keep this leaflet. You may need to read it again. If you have any further questions, ask your doctor, pharmacist or nurse. This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. What is in this leaflet 1. What Desloratadine 5 mg Tablets are and what they are used for 2. What you need to know before you take Desloratadine 5 mg Tablets 3. How to take Desloratadine 5 mg Tablets 4. Possible side effects 5. How to store Desloratadine 5 mg Tablets 6. Contents of the pack and other information 1. What Desloratadine 5 mg Tablets are and what they are used for What Desloratadine 5 mg Tablets is Desloratadine 5 mg Tablets contain desloratadine which is an antihistamine. How Desloratadine 5 mg Tablets works Desloratadine 5 mg Tablets is an antiallergy medicine that does not make you drowsy. It helps control your allergic reaction and its symptoms. When Desloratadine 5 mg Tablets should be used Desloratadine relieves symptoms associated with allergic rhinitis (inflammation of the nasal passages caused by an allergy, hay fever or allergy to dust mites) in adults and adolescents 12 years of age and older. -
Medication Instructions for Allergy Patients
MEDICATION INSTRUCTIONS FOR ALLERGY PATIENTS Drugs which contain antihistamine or have antihistaminic effects can result in negative reactions to skin testing. As a result, it may not be possible to properly interpret skin test results, and testing may have to be repeated at a later date. While this list is extensive, it is NOT all inclusive (particularly of the various brand names). Discontinue ALL antihistamines including the following medications seven (7) days prior to skin testing (unless longer time specified): Antihistamines – Generic name (Brand name(s)): Cetirizine (Zyrtec, Zyrtec-D) Hydroxyzine (Vistaril, Atarax) Desloratadine (Clarinex) Levocetirizine (Xyzal) Fexofenadine (Allegra, Allegra-D) Loratadine (Claritin, Claritin-D, Alavert) Diphenhydramine (Aleve PM, Benadryl, Bayer P.M., Benylin, Contac P.M., Doans P.M, Excedrin PM, Legatrin P.M.. Nytol, Tylenol Nighttime, Unisom, Zzzquil) Chlorpheniramine (Aller-Chlor, Allerest, Alka Seltzer Plus, Chlor-Trimeton, Comtrex, Contac, Co-Pyronil, Coricidin, CTM, Deconamine, Dristan, Dura-tap, Naldecon, Ornade Spansules, Rondec, Sinutab, Teldrin, Triaminic, Triaminicin, Tylenol Allergy) Azatadine (Optimine, Trinalin) Doxylamine (Nyquil) Brompheniramine (Bromfed, Dimetane, Dimetapp) Meclizine (Antivert) Carbinoxamine (Clistin, Rondec) Pheniramine Clemastine (Tavist) Phenyltoloxamine (Nadecon) Cyclizine (Marezine) Promethazine (Phenergan) Cyprohepatidine (Periactin) (9 days) Pyrilamine (Mepyramine) Dexbrompheniramine (Drixoral) Quinacrine (Atabrine) Dexchlorpheniramine (Extendryl, Polaramine) -
QSAR Modeling
Best practices for developing predictive QSAR models Alexander Tropsha Laboratory for Molecular Modeling and Carolina Center for Exploratory Cheminformatics Research School of Pharmacy UNC-Chapel Hill OUTLINE • Introduction: Brief outline of the QSAR approach • Why models fail (bad practices) • Good practices. – Predictive QSAR Modeling Workflow – Examples of the Workflow applications – Emerging applications of QSAR: chemocentric informatics • Conclusions: QSAR modeling is a decision support The rumors of QSAR demise have been greatly exaggerated 100,000 4500 90,000 4000 number of QSAR 80,000 Number of compounds papers in PubMed 3500 70,000 in CAS (in 1000s) 3000 60,000 2500 50,000 2000 40,000 Number of protein 1500 Structures in PDB 30,000 1000 20,000 500 10,000 0 0 1972 1974 1976 1978 1980 1982 1984 1986 1988 1990 1992 1994 1996 1998 2000 2002 2004 2006 1972 1974 1976 1978 1980 1982 1984 1986 1988 1990 1992 1994 1996 1998 2000 2002 2004 2006 Graphs are courtesy of Prof. A. Cherkasov Principles of QSAR modeling Introduction O N C 0.613 O O N 0.380 A -0.222 O D C M N O E 0.708 N S O Quantitative 1.146 T P N C O R 0.491 N Structure I O I 0.301 O P Activity N 0.141 V U O T Relationships N O 0.956 I N O R N 0.256 S D 0.799 T O 1.195 N Y S 1.005 Principles of QSAR/QSPR modeling Introduction O N C 0.613 O O N 0.380 P -0.222 O D R M N O E 0.708 N S O Quantitative 1.146 O P N C O R 0.491 N Structure P O I 0.301 O P Property N 0.141 E U O T Relationships N O 0.956 R N O R N 0.256 S D 0.799 T O 1.195 N Y S 1.005 The utility of QSAR models CHEMICAL -
Partial Agreement in the Social and Public Health Field
COUNCIL OF EUROPE COMMITTEE OF MINISTERS (PARTIAL AGREEMENT IN THE SOCIAL AND PUBLIC HEALTH FIELD) RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies, and superseding Resolution AP (82) 2) AND APPENDIX I Alphabetical list of medicines adopted by the Public Health Committee (Partial Agreement) updated to 1 July 1988 APPENDIX II Pharmaco-therapeutic classification of medicines appearing in the alphabetical list in Appendix I updated to 1 July 1988 RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (superseding Resolution AP (82) 2) (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies) The Representatives on the Committee of Ministers of Belgium, France, the Federal Republic of Germany, Italy, Luxembourg, the Netherlands and the United Kingdom of Great Britain and Northern Ireland, these states being parties to the Partial Agreement in the social and public health field, and the Representatives of Austria, Denmark, Ireland, Spain and Switzerland, states which have participated in the public health activities carried out within the above-mentioned Partial Agreement since 1 October 1974, 2 April 1968, 23 September 1969, 21 April 1988 and 5 May 1964, respectively, Considering that the aim of the Council of Europe is to achieve greater unity between its members and that this -
Volume 25, Issue 8 April 23, 2020
April 23, 2020 Volume 25 Issue 8 SPECIAL EDITION COVID-19 Error-prone dose expression on label of COVID-19 Collaboration unapproved drug, ascorbic acid, from Mylan Tripping on extension tubing PROBLEM : A pharmacist received an order for 500 mg of intravenous (IV) ascorbic A COVID-19 patient was being treated in acid for a patient with coronavirus (COVID-19). Although this product was on an intensive care unit (ICU) in a negative formulary at the hospital, it was rarely used prior to the COVID-19 pandemic, and pressure room. An ICU nurse had seen a the pharmacist had never dispensed it. (In COVID-19 investigational trials, IV ascorbic post on social media about another facility acid is being used in much larger doses placing smart infusion pumps outside of [i.e., 10 or 12 g] after being added to an patient rooms to help minimize the use of appropriate diluent, with the theory that it personal protective equipment (PPE). She will hasten recovery.) decided to implement this workflow. She moved the infusion pump to an anteroom After selecting the available vial of ascorbic outside the patient’s negative pressure acid injection (Mylan), the pharmacist room, and used extension sets to run the noticed that the principal display panel on tubing under the door and to the patient. the carton and vial label indicated that it The patient was receiving intravenous contained 500 mg/mL ( Figure 1 ). This is in (IV) norepinephrine via the infusion pump conflict with USP <7>, which requires most to treat hypotension. The extension tubing medication labels to list the total amount of was on the floor and not secured to drug and volume in the vial (with the per Figure 1. -
Alternative Forms of Oral Drug Delivery for Pediatric Patients Marcia L
PEDIATRIC PHARMACOTHERAPY A Monthly Newsletter for Health Care Professionals from the University of Virginia Children’s Hospital Volume 19 Number 3 March 2013 Alternative Forms of Oral Drug Delivery for Pediatric Patients Marcia L. Buck, Pharm.D., FCCP, FPPAG he lack of an appropriate dosage form the concentration versus time curve (AUC) of T limits the use of many medications that 45% for lopinavir and 47% for ritonavir (p = may potentially benefit children. While this has 0.003 and 0.006, respectively). been a long-standing problem for pediatric healthcare providers, little attention has been Cutting tablets, another common practice, may paid to remedying it until recently. In 2005 the be acceptable for some drugs, however this Eunice Kennedy Shriver National Institute for practice can introduce considerable variability Child Health and Human Development, joined between doses. In drugs with a narrow by representatives from the Food and Drug therapeutic index, such as levothyroxine, this Administration (FDA), academic medicine, and variability may be enough to produce clinically the pharmaceutical industry, formed the United significant changes in clinical response.7 When States (US) Pediatric Formulations Initiative in cutting a tablet is necessary, family members an effort to stimulate research in pediatric should receive specific instructions on the formulation technology.1 Similar work by the process, including the proper use of a tablet European Medication Agency (EMA) led to the splitter. Family members involved in dose development of the European Pediatric preparation should also understand how to Formulation Initiative.2 In addition, the World dispose of unused drug and the need to avoid Health Organization launched a global initiative repeated exposure to drugs that have in 2007 entitled “Make Medicines Child Size” to carcinogenic or teratogenic properties. -
Evaluation of the Efficacy of the Utilization of the Imipramine For
vv Clinical Group Archives of Otolaryngology and Rhinology ISSN: 2455-1759 DOI CC By Diaa El Din El Hennawi, Mohamed Rifaat Ahmed*, Yasser T Madian, Research Article Mohammed T El-Tabbakh and Ibrahim Hassan Ibrahim Evaluation of the efficacy of the Department of Otorhinolaryngology, Faculty of utilization of the imipramine for medicine Suez Canal University, Ismailia – Egypt Dates: Received: 13 May, 2017; Accepted: 22 July, patients with allergic rhinitis 2017; Published: 26 July, 2017 *Corresponding author: Mohamed Rifaat Ahmed, MD, Assistant Professor, Otolaryngology, Fac- ulty of Medicine, Suez Canal University, Ismailia, Abstract Egypt, Tel: +201285043825; Fax: +20663415603; E-mail: Background: allergic rhinitis is an infl ammatory process of the upper respiratory tract with a continuous symptom that last for hour or more with symptom affect patient’s work and quality of life. Keywords: Allergic rhinitis; Imipramine; Desloratadine; Randomized controlled trial Methodology: a randomized controlled trial in which we enrolled 284 patients with allergic rhinitis for periods longer than 4 days/week and for more than 4 consecutive weeks divided into two groups. https://www.peertechz.com Group A (n=142) received Imipramine 75 mg/day for 90 days .Group B (n=142), the control group, received desloratadine 5 mg / day for 90 days. Results: The mean visual analogue score nasal symptoms intensity (sneezing, Nasal obstruction, watery rhinorrhea and itchy nose) showed a statistically signifi cantly improvement in group A (treated with Imipramine) compared with group B (treated with desloratadine) after the same treatment period. Conclusion: Imipramine could be used in treatment patients with allergic rhinitis as it is effective as an antihistaminic besides its main action in reliving psychosocial stresses.